Cytokine regulation of apoptosis in hematopoietic precursor cells

Current Opinion in Hematology

Volumn 3, Issue 3, 1996, Pages 191-196

  Park, Julie R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL DEATH; CELL SURVIVAL; HEMATOPOIETIC STEM CELL; PRIORITY JOURNAL; PROTO ONCOGENE; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029900071     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603030-00005     Document Type: Review

References (62)

1. Raff MC: Social controls on cell survival and cell death. Nature 1992, 356:397-400.
2. Savill J, Wyllie A, Walport M, Henson P, Haslett C: Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989, 83:865-875.
3. Lopez A, Williamson D, Gamble J, Begley C, Harlan J, Klebanoff S. Waltersdorph A, Wong G, Clark S, Vadas M: Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro human neutrophil and eosinophil function, surface receptor expression and survival. J Clin Invest 1986, 78:1220-1228.
4. Mangan D, Wahl S: Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 1991, 147:3408-3412.
5. Yamaguchi Y, Suda T, Oath S, Tominaga K, Miura Y, Kashara T: Analysis of the survival of mature eosinophils: interleukin-5 prevents apoptosis in mature eosinophils. Blood 1991, 78:2542-2547.
6. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovi: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80:2012-2020.
7. Sachs L, Lotem J: Apoptosis in the hemopoietic system. In Apoptosis and the Immune Response. Wiley-Liss, Inc; 1995:371-403.
8. Williams G, Smith C, Spooncer E, Dexter T, Taylor D: Haematopoietic colony stimulating factors promote survival by suppressing apoptosis. Nature 1990, 343:76-79.
9. Koury M: Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 1992, 20:391-394.
10. Metcalf D: Hematopoletic regulators: redundancy or subtlety? Blood 1993, 82:3515-3523.
11. Whetton AD, Dexter TM: Influence of growth factors and substrates on differentiation of haemopoietic stem cells. Curr Opin Cell Biol 1993, 5:1044-1049.
12. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993, 82:15-21.
13. Koury M, Bondurant M: Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990, 248:378-381.
14. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergizes with GM-CSF, G-CSF, IL-3, and Epo to stimulate human progenitor cells of myeloid and erythroid lineages. Exp Hematol 1991, 19:226-231.
15. Caceres-Cortes J, Rajotte D, Dumouchel J, Haddad P, Hoang T: Product of the Steel locus suppresses apoptosis in hemopoietic cells. J Biol Chem 1994, 269:12084-12091.
16. Muta K, Krantz SB, Bondurant MC, Dai C: Stem cell factor retards dif• ferentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood 1995, 86:572-580. Stem cell factor enhances proliferation and inhibits differentiation of erythroid precursor cells in vitro without affecting cell viability.
17. Ottmann O, Pelus L: Differential proliferation effects of transforming growth factor β on human hematopoietic progenitor cells. J Immunol 1988, 140:2661-2665.
18. Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992, 80:1750-1757.
19. Jacobsen F, Stokke T, Jacobsen S: Transforming growth factor-β •• potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Blood 1995, 86:2957-2966. In an important attempt to understand the molecular effects of inhibitory cytokines, this paper demonstrates that TGF-β induces apoptosis in nontransformed murine hematopoietic progenitor cells. The authors further demonstrate that TGF-β counteracts the survival-promoting effects of stem cell factor.
20. low cells in which anti-TGF-β upmodulates c-kit. Blood 1995, 86:1729-1735. As a potential explanation for TGF- inhibition of hematopoietic precursor cell clonogenicity, the authors demonstrate that the expression of c-kit on primitive hematopoietic precursor cells is rapidly downmodulated following exposure to TGF-β.
21. Broxmeyer H, Williams D, Lu L, Cooper S, Anderson S, Beyer G, Hoffman R, Rubin B: The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986, 136:4487-4495.
22. Maciejewski J, Selleri C, Sato T, Cho H, Keefer L, Nathan C, Young N: Nitric oxide suppression of human hematopoiesis in vitro: contribution to inhibitory action of interferon-γ tumor necrosis factor-α. J Clin Invest 1995, 96:1085-1092. The authors suggest a role for nitric oxide production and subsequent induction of apoptosis in the inhibition of hematopoietic precursor survival by interferon gamma and TNF-α.
23. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
24. Oehm A, Behrman I, Falk W, Pawlita M: Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992, 267:10709-10715.
25. Yoshino T, Kondo E, Cao L, Takahashi K, Hayashi K, Nomura S, Akagi T: Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 1994, 83:1856-1861.
26. Maciejewski J, Selleri C, Anderson S, Young NS: Fas antigen expression •• on CD34+ human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995, 85:3183-3190. The first data (see also Nagafuji et al. [Blood 1995, 86:883-889]) to support a role for the Fas pathway as a potential mechanism for interferon gamma and TNF-α inhibition of hematopoietic cell survival. Exposure of hematopoietic precursor cells to interferon gamma and TNF-α results in the induction of Fas expression. Subsequent treatment of cells with an anti-Fas antibody that mimics Fas ligand leads to hematopoietic precursor cell apoptosis and decreased in vitro clonogenicity.
27. Nagafuji K, Shibuya T, Harada M, Mizuno S, Tadenaka K, Miyamoto T, •• Okamura T, Gondo H, Niho Y: Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995, 86:883-889. Similar to the work of Maciejewski et al. (Blood 1995, 85:3183-3190), these authors also demonstrate the ability of interferon gamma and TNF-α to upregulate Fas expression, thereby allowing the potential induction of apoptosis in hematopoietic precursor cells.
28. Enari M, Huh H, Nagata S: Involvement of an ICE-like protease in Fas-•• mediated apoptosis. Nature 1995, 375:78-80. This important finding links interleukin-1β-converting enzyme, a protease known to be important in the apoptotic signal transduction, with Fas- and TNF-α-mediated regulation of cell death. The expression of crmA, an inhibitor of interleukin-1β-converting enzyme, blocks cell death induced by either anti-Fas antibody or TNF-α.
29. Los M, Van de Craen M, Penning L, Schenk H, MW, Baeuerle P, Droge •• W, Krammer P, Fiers W, Schulze-Osthoff K: Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995, 375:81-83. Similar to the results of Enari et al. (Nature 1995, 375:78-80) these data demonstrate that expression of crmA or antisense interleukin-1β-converting enzyme construct can inhibit Fas-mediated cell death. They also demonstrate that Fas signaling leads to increased interleukin-1β-converting enzyme proteolytic activity and that overexpression of interleukin-1β-converting enzyme can potentiate Fas-mediated cell death.
30. Tsujimoto Y, Finger L, Yunis J, Nowell P, Croce C: Cloning the chromosome breakpoint of neoplastic B-cells with the t(14;18) chromosome translocation. Science 1984, 226:1097-1099.
31. Bakhshi A, Jensen J, Goldman P, Wright J, McBride O, Epstein A, Korsmeyer S: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41:899-906.
32. Cleary M, Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985, 82:7439-7443.
33. Hockenbery D, Nunez G, Milliman C, Schreiber R, Korsmeyer S: Bcl-2 protein is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
34. McDonnell T, Deane N, Platt F, Nunez G, Jaeger U, McKearn J, Korsmeyer S: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989, 57:79-88.
35. Hengartner M, Horvitz H: C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994, 76:665-676.
36. Boise L, Gonzales-Garcia M, Postema C, Ding L, Lindsten T, Turka L, Mao X, Nunez G, Thompson C: Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
37. Reynolds J, Yang T, Qian L, Jenkinson D, Zhou P, Eastman A, Craig R: Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-myc overexpression in Chinese hamster ovary cells. Cancer Res 1994, 54:6348-6352.
38. Oltvai Z, Milliman C, Korsmeyer S: Bcl-2 heterodimerizes in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
39. Farrow S, White J, Martinou I, Raven T, Pun K, Grinham C, Martinou J, Brown R: Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374:731-733.
40. Chittenden T, Harrington E, O'Connor R, Flemington C, Lutz R, Evan G, Guild B: Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995, 374:733-736.
41. Kiefer M, Brauer M, Powers V, Wu J, Umansky S, Tomei L, Barr P: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995, 374:736-739.
42. Yang E, Zha J, Jockel J, Boise L, Thompson C, Korsmeyer S: Bad, a heterodimeric partner for bcl-xL and bcl-2, displaces bax and promotes cell death. Cell 1995, 80:285-291.
43. Vaux D, Cory S, Adams J: Bcl-2 gene promotes hemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442.
44. Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer S: Bcl-2 protein is topographically restricted in tissues characterized by apoptotlc cell death. Proc Natl Acad Sci U S A 1991, 88:6961-6965.
45. Krajewski S, Krajewski M, Shabaik A, Wang H, Irie S, Fong L, Reed J: Immunohistochemical analysis of in vivo patterns of bcl-x expression. Cancer Res 1994, 54:5501-5507.
46. Delia D, Aiello A, Soligo D, Fontella E, Melani C, Pezzella F, Pierotti M, Della Porta G: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992, 79:1291-1298.
47. Park J, Bernstein I, Hockenbery D: Primitive human hematopoietic pre•• cursors express Bcl-x but not Bcl-2. Blood 1995, 86:868-876. Our findings suggest differential roles of Bcl-x and Bcl-2 in the maintenance of hematopoietic precursor survival. We also demonstrate cytokine-mediated induction of Bcl-2 expression in primitive hematopoietic precursor cells, providing a potential mechanism for cytokine-mediated regulation of precursor survival.
48. Motoyama N, Wang F, Roth K, Sawa H, Nakayama K, Nakayama K, •• Negishi I, Senju S, Zhang Q, Satoshi F, Loh D: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficlent mice. Science 1995, 267:1506-1510. These knockout mice die during embryogenesis and exhibit neuronal and hematopoietic progenitor cell death. This is in striking contrast to Bcl-2-deficient mice, which appear normal at birth and do not exhibit neuronal or non-lymphoid hematopoietic dysfunction.
49. Nunez G, London L, Hockenbery D, Alexander M, McKearn K, Korsmeyer S: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J Immunol 1990, 144:3602-3610.
50. Bradbury D, Zhu Y, Russell N: Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 1994, 8:786-791.
51. Lotem J, Sachs L: Regulation of bcl-2, bcl-xL and bax in the control of • apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995, 6:647-653. The authors demonstrate interleukin-6 and GM-CSF-induced expression of Bcl-x in myeloid leukemic cell lines and subsequent resistance to the induction of apoptosis by Adriamycin (Adria Laboratories, Columbus, OH) or cycloheximide.
52. Quelle F, Sato N, Witthuhn BA, Inhorn R, Eder M, Miyajima A, Griffin J, Ihle J: JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol 1994, 14:4335-4341.
53. Sato N, Sakamaki K, Terada N, Arai K, Miyajima A: Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 1993, 12:4181-4189.
54. Kinoshita T, Yokota T, Arai K, Miyajima A: Suppression of apoptotic •• death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors. EMBO J 1995, 14:266-275. These investigators demonstrate distinct cytokine receptor signaling pathways for the induction of DNA synthesis and the prevention of apoptosis. By examining the differential effects of protein kinase inhibitors and deletional mutations of the GM-CSF receptor β-chain, they implicate kinases of the Ras pathway as important mediators for prevention of apoptosis. Finally, activated Ras can functionally replace the GM-CSF receptor domain necessary for the prevention of apoptosis.
55. Inhorn R, Carlesso N, Durstin M, Frank D, Griffin J: Identification of a via•• bility domain in the granulocyte macrophage colony-stimulating factor receptor β-chain involving tyrosine-750. Proc Natl Acad Sci U S A 1995, 92:8665-8669. By analyzing deletional mutants of the GM-CSF receptor β-chain, these authors characterize domains that function to inhibit apoptosis. They identify that tyrosine-750 of the receptor β-chain is necessary for receptor-mediated antiapoptotic signaling. Reduced phosphorylation of she also results from this single tyrosine mutation, suggesting a role for this kinase in cytokine receptor-mediated regulation of cell survival.
56. Carroll M, May W: Protein kinase C mediated serine phosphorylation directly activates raf-1 in murine hematopoietic cells. J Biol Chem 1994, 269:1249-1256.
57. Wang H, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L, Troppmair J, Rapp U, Reed J: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994, 9:2751-2756.
58. Rinaudo M, Su K, Falk L, Haldar S, Mufson R: Human interleukin-3 •• receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 1995, 86:80-88. Inhibitors of protein kinase C result in decreased expression of Bcl-2 and induction of apoptosis despite the presence of interleukin-3, suggesting a role for protein kinase C in interleukin-3-induced expression of Bcl-2 and suppression of apoptosis.
59. Nakamura Y, Komatsu N, Nakauchi H: A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science 1992, 257:1138-1141.
60. Zhuang H, Niu Z, He T, Patel S, Wojchowski D: Erythropoietin-depen•• dent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2. J Biol Chem 1995, 270:14500-14505. These authors demonstrate a requirement for Jak2 kinase in erythropoietin receptor-mediated suppression of apoptosis. This is in contrast to studies of the homologous domains of the interleukin-3 and GM-CSF receptors (see Kinoshita et al. [EMBO J 1995, 14:266-275] and Inhorn et al. [Proc Natl Acad U S A 1995, 26:8665-8669]), which demonstrate that the activation of Jak2 is not sufficient for the suppression of apoptosis.
61. Zhuang H, Patel S, He T, Sonsteby S, Niu Z, Wojchowski D: Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J Biol Chem 1994, 269:21411-21414.
62. Yin X, Oltvai Z, Korsmeyer S: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369:321-323.